The Pfizer-BioNTech COVID-19 vaccine designed to target the Omicron virus variant could be ready for administration as soon as April while Moderna’s COVID-19 vaccine booster designed to neutralize the variant may be ready by August.
Trial data on Pfizer-BioNTech jab is on track to be ready for dissemination to regulatory agencies by the end of March but regulators will likely not clear it that month, BioNTech CEO Ugur Sahin told Germany’s Bild newspaper on Feb. 17.
